vatalanib has been researched along with sb 225002 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (sb 225002) | Trials (sb 225002) | Recent Studies (post-2010) (sb 225002) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 92 | 0 | 73 |
| Protein | Taxonomy | vatalanib (IC50) | sb 225002 (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.022 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0623 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achyut, BR; Angara, K; Ara, R; Arbab, AS; Bollag, RJ; Borin, TF; Iskander, A; Lebedyeva, I; Lin, PC; Rashid, MH | 1 |
1 other study(ies) available for vatalanib and sb 225002
| Article | Year |
|---|---|
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Interleukin-8; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Phthalazines; Pyridines; Rats, Nude; Receptors, Interleukin-8B; Tissue Array Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |